杭州银行(600926.SH)首三季净利润按年增5.1% 计提拨备按年增28%
杭州银行(600926.SH)发布第三季度报告显示,首三季归属於母公司股东的净利润55.77亿元人民币(下同),按年增长5.11%。基本每股收益1元。
期内,营业收入186.52亿元,按年增长16.24%;实现减值损失前营业利润138.9亿元,按年增长18.51%;计提信用减值损失74.33亿元,较上年同期增长27.95%。利息净收入140.99亿元,按年增长24.36%;手续费及佣金净收入25.2亿元,按年增长93.68%。
在资产质量方面,截至9月末,该行不良贷款率1.09%,较上年末下降0.25个百分点;拨备覆盖率453.16%,较上年末提升136.45个百分点。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.